Relapsed/Refractory Multiple Myeloma Clinical Trial
Official title:
A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to assess in real-life clinical practice, over a 24-month period, the effectiveness and safety of current standard of care (SOC) antimyeloma treatments in participants with previously treated relapsed and/or refractory multiple myeloma.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05427812 -
Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04093596 -
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)
|
Phase 1 | |
| Not yet recruiting |
NCT05498545 -
Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT04973605 -
A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05376345 -
BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma
|
Phase 1 | |
| Withdrawn |
NCT05980507 -
An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma
|
Phase 1 | |
| Active, not recruiting |
NCT04601935 -
A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple Myeloma
|
Phase 1 | |
| Terminated |
NCT06160609 -
Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
|
Phase 1/Phase 2 | |
| Completed |
NCT03309111 -
Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT06049290 -
A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05259839 -
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
|
Phase 1 | |
| Terminated |
NCT03318861 -
Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma
|
Phase 1 | |
| Active, not recruiting |
NCT03590652 -
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT01794520 -
Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
| Terminated |
NCT04142619 -
Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)
|
Phase 1 | |
| Completed |
NCT01849848 -
Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT01794507 -
A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
|
Phase 1 | |
| Terminated |
NCT03287908 -
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT05862012 -
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT03489525 -
MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
|
Phase 1 |